Home › Therapeutic areas › Neurology › Major Depressive Disorder
Major Depressive Disorder (13 companies)
Companies with an active program in Major Depressive Disorder.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ANRO | Alto Neuroscience | Neurology | 4 | Phase 2 | $999M | 6 |
| ATAI | Atai Beckley | Neurology | 3 | Phase 2 | $2.73B | 5 |
| AXSM | Axsome Therapeutics | Neurology Rare | 2 | Approved | $7.15B | 15 |
| CMPS | COMPASS Pathways | Neurology | 1 | NDA Submitted | $1.13B | 3 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $375M | 4 |
| DFTX | Definium Therapeutics | Neurology | 1 | Phase 3 | $4.02B | 4 |
| GHRS | GH Research | NeurologyWomen's Health | 2 | Phase 2 | $1.25B | 4 |
| HELP | Helus Pharma | Neurology | 1 | Phase 3 | $575M | 3 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.30B | 3 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 4 | Approved | $109M | 11 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 2 | Phase 3 | $4.7M | 11 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 1 | NDA Submitted | $3.81B | 9 |
No companies match.